Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: A combined analysis

Catheterization and Cardiovascular Interventions

Volumn 65, Issue 2, 2005, Pages 212-221

  Borentain, Maria ^a   Montalescot, Gilles ^a   Bouzamondo, Anissa ^a   Choussat, Rémi ^a   Hulot, Jean Sébastien ^a   Lechat, Philippe ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Anticoagulants; Myocardial infarction; Myocardial revascularization; Safety; Treatment efficacy

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN; TICLOPIDINE;

ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; DEATH; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MALE; META ANALYSIS; MONITORING; PERCUTANEOUS CORONARY INTERVENTION; STABLE ANGINA PECTORIS; SYSTEMATIC REVIEW;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFUSIONS, INTRAVENOUS; POSTOPERATIVE HEMORRHAGE; TREATMENT OUTCOME;

EID: 20344374735     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20352     Document Type: Article

References (51)

1. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-1608.
2. Simoons M, Krzeminska-Pakula M, Alonso A, Goodman S, Kali A, Loos U, Gosset F, Louer V, Bigonzi F, AMI-SK investigator. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. Eur Heart J 2002;23:1282-1290.
3. Ross AM, Molhoek P, Lundergan C, Knudtson M, Draoui Y, Regalado L, Le Louer V, Bigonzi F, Schwartz W, de Jong E, Coyne K, HART II investigators. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin. Circulation 2001;104:648-652.
4. Antman EM, Louwerenburg HW, Baars HF, Wesdorp JC, Hamer B, Bassand JP, Bigonzi F, Pisapia G, Gibson CM, Heidbuchel H, Braunwald E, Van de Werf F. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation 2002;105:1642-1649.
5. Baird SH, Menown IB, Mcbride SJ, Trouton TG, Wilson C. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J 2002;23:627-632.
6. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.
7. Tatu-Chitoiu G, Teodorescu C, Fluerasu A, Capraru P, Guran M, Dan M, Chioncel V, Bumbu A, Cornaciu S. Accelerated streptokinase: a new thrombolytic regimen in acute myocardial infarction. Rom J Intern Med 1998;36:183-196.
8. Wallentin L, Dellborg DM, Lindahl B, Nilsson T, Pehrsson K, Swahn E. The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study. Clin Cardiol 2001;24(3 Suppl):I12-I14.
9. Frostfeldt G, Ahlberg G, Gustafsson G, Helmius G, Lindahl B, Nygren A, Siegbahn A, Swahn E, Venge P, Wallentin L. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction: a pilot study-biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol 1999;33:627-633.
10. Theroux P, Welsh RC. Meta-analysis of randomized trials comparing enoxaparin versus unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction. Am J Cardiol 2003;91:860-864.
11. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-452.
12. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601.
13. Cohen M, Antman EM, Gurfinkel E, Turpie AG, Furst J, Bigonzi F, Radley D. Impact of enoxaparin low molecular weight heparin in patients with a Q-wave myocardial infarction. Am J Cardiol 2000; 86:553-556.
14. Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, Sotirov I, Thomas D. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-663.
15. Martin JL, Fry ETA, Serano A, Atherley TH, Ozoux ML, Guimart C, Chevalier P, Bigonzif F, Pensyl C, Sanderink GJ. Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes: the PEPCI study. Eur Heart J 2001;22(Suppl):14.
16. Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, Pepine CJ, Theroux P, NICE 3 investigators. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: final results of the NICE 3 study. J Am Coll Cardiol 2001;37(Suppl A):365A.
17. Fox KA, Antman EM, Cohen M, Bigonzi F, ESSENCE/TIMI 11B investigators. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Am J Cardiol 2002;90:477-482.
18. Cohen M. The role of low-molecular-weight heparins in the management of unstable angina and non-ST-segment elevation myocardial infarction. J Thromb Thrombolysis 2001;11:171-174.
19. Samama MM, Bara L, Gerotziafas GT. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis 1994;24:105-117.
20. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-256.
21. Montalescot G, Bal-dit-Sollier C, Chibedi D, Collet JP, Soulat T, Dalby M, Choussat R, Cohen A, Slama M, Steg PG, Dubois-Rande JL, Metzger JP, Tarragano F, Guermonprez JL, Drouet L, ARMADA investigators. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol 2003;91:925-930.
22. Montalescot G, Collet JP, Lison L, Choussat R, Ankri A, Vieaut E, Perlemuter K, Philippe F, Drobinski G, Thomas D. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000;36: 110-114.
23. Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, Carrie D, Flammang D, Dutoit A, Carayon A, Jardel C, Chevrot M, Bastard JP, Bigonzi F, Thomas D. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin-French investigators of the ESSENCE trial. Circulation 1998;98:294-299.
24. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). J Am Coll Cardiol 1996;28:1437-1443.
25. Rabah MM, Premmereur J, Graham M, Fareed J, Hoppensteadt DA, Grines LL, Grines CL. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391-1395.
26. Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, Corrigan VE, Ryan TJ Jr, Breall JA, Moses JW, Eaton GM, Sklar MA, Lincoff AM. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single Bolus Enoxaparin Study. J Am Coll Cardiol 2003; 41:20-25.
27. Galeote G, Hussein M, Sobrino N, Calvo L, Yunda H, Sánchez-Recalde A, Sobrino JA. Combination abciximab and enoxaparin or unfractionated heparin during percutaneous coronary intervention: a randomised study. Eur Heart J 2001;22(Suppl):663.
28. Dudek D, Dabrowski M, Ochala A, Lesaik M, Wnek A, Bryniarski L, Zmudka K, Zymek P, Dubeil JS, Gil R, on behalf of the study group. Multicenter, prospective, double-blind randomized comparison of enoxaparin versus unfractionated heparin for percutaneous coronary interventions. Am J Cardiol 2000;86(Suppl 8A):15i.
29. Dudek D, Bartus S, Zymek P, Legutko J, Rzeszutko L, Janion M, Zumudka K, Dubeil JS. Abciximab and enoxaparin administration during elective high-risk PTCA in patients with more than 3 days of ticlopidine pretreatment. J Am Coll Cardiol 2000;35(Suppl): 91A.
30. Drozd J, Opalińska E, Wojcik J. Madejczyk A. The use of enoxaparin during percutaneous coronary angioplasty in patients with stable angina. Kardiol Pol 2001;55:520-524.
31. Natarajan MK, Turpie GA, Raco DL, Velianon JL, Mehta SR, Afzal R, Goodhart PR, Ginsberg JS. A randomized comparison of dalteparin versus unfractioned heparin during percutaneous coronary interventions. J Am Coll Cardiol 2003;41(Suppl A):68A-69A.
32. Kereiakes DJ, Grines C, Fry E, Esente P, Hoppensteadt D, Midei M, Barr L, Matthai W, Todd M, Broderick T, Rubinstein R, Fareed J, Santoian E, Neiderman A, Brodie B, Zidar J, Ferguson JJ, Cohen M, NICE 1 and NICE 4 investigators. National Investigators Collaborating on Enoxaparin: enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invas Cardiol 2001;13:272-278.
33. Chen WH, Lau CP, Lau YK, Ng W, Lee PY, Yu CM, Ma E. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invas Cardiol 2002;14:439-442.
34. Miller L, Gupta A, Bertolet BD. Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes. J Invas Cardiol 2002;14:247-250.
35. Kereiakes DJ, Kleiman NS. Fry E, Mwawasi G, Lengerich R, Maresh K, Burkert ML, Aquilina JW, DeLoof M, Broderick TM, Shimshak TM. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001; 141:348-352.
36. Sheldon WS, O'Shaughnessy CD, Farhat NZ, Lankenship DC, Sinth D. Dalteparin (fragmin) in percutaneous coronary and peripheral intervention. Am J Cardiol 2002;90(Suppl 6A):155H.
37. Choussat R, Montalescot G, Collet JP, Beygui F, Le Feuvre C, Ankri A, Drobinski G, Sotirov Y, Metzger J-P. A single and low dose of intravenous enoxaparin (0.5mg/kg) in elective percutaneous coronary intervention. Circulation 2002;106(Suppl 2):11518.
38. Cucherat M, Boissel JP, Leizorovicz A, Haugh MC. Easy MA: a program for the meta-analysis of clinical trials. Comput Methods Programs Biomed 1997;53:187-190.
39. Montalescot G, Cohen M. Low molecular weight heparins in the cardiac catheterization laboratory. J Thromb Thrombolysis 1999; 7:319-323.
40. Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA 2003; 289:331-342.
41. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams DO, Gibbons RJ, Alpert JP, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO, Smith SC Jr. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines): executive summary - a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 2001;37:2215-2239.
42. Popma JJ, Ohman EM, Weitz J, Lincoff AM, Harrington RA, Berger P. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 2001;119(1 Suppl):321S-336S.
43. Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, Topol EJ. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001; 103:961-966.
44. Tolleson TR, O'Shea JC, Bittl JA, Hillegass WB, Williams KA, Levine G, Harrington RA, Tcheng JE. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol 2003;41:386-393.
45. Moliterno DJ, Hermiller JB, Kereiakes DJ, Yow E, Applegate RJ, Braden GA. Dippel EJ, Furman MI, Grines CL, Kleiman NS, Levine GN, Mann T III, Nair RN, Stine RA, Yacubov SJ, Tcheng JE, ELECT investigators. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention: results of the Evaluating Enoxaparin Clotting Times (ELECT) study. J Am Coll Cardiol 2003;42:1132-1139.
46. Michails LK, Katsouras CS, Papamichael N, Adamides K, Naka KK, Goudevenos J, Sideris DA. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J 2003;146:304-310.
47. Montalescot G, Bal-dit-Sollier C, Chibedi D, Collet JP, Soulat T, Dalby M, Choussat R, Cohen A, Slama M, Steg PG, Dubois-Rande JL, Metzger JP, Tarragano F, Guermonprez JL, Drouet L, ARMADA investigators. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol 2003;91:925-930.
48. Marmur JD, Anand SX, Bagga RS, Fareed J, Pan CM, Sharma SK, Richard MF. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 2003;41:394-402.
49. Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Pieper K, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL III, Michelson AD. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: effects of dalteparin or unfractionated heparin in combination with abciximab. Am Heart J 2001;142:790-798.
50. Madan M, Radhakrishnan S, Pang JT, Della Siega AJ, Reis M, Paradiso-Hardy FL, Fort S, Naqui SZ, Cohen EA. Optimal anticoagulation and platelet inhibition are achieved when enoxaparin is combined with small molecule glycoprotein IIb/IIIa inhibition during elective percutaneous coronary intervention. Circulation 2001;104(Suppl2):II385.
51. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC. Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H, SYNERGY trial investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292: 45-54.